How many drugs treat Meningeal Leukemia?

Drug Landscape tracks 3 marketed treatments for Meningeal Leukemia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/meningeal-leukemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Meningeal Leukemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Meningeal Leukemia (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Meningeal Leukemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cytarabine	Cytarabine	Nippon Shinyaku Co., Ltd.	Antimetabolite	DNA polymerase	1969-01-01
Trexall	methotrexate	Generic (originally Lederle Laboratories)	Antifolate, DMARD	Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4	1953-12-07
Methotrexat	Methotrexat	Biocad		Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Biocad · 1 drug in Meningeal Leukemia
Generic (originally Lederle Laboratories) · 1 drug in Meningeal Leukemia
Nippon Shinyaku Co., Ltd. · 1 drug in Meningeal Leukemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Meningeal Leukemia:

Cite this brief

Drug Landscape (2026). Meningeal Leukemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/meningeal-leukemia. Accessed 2026-06-10.

Meningeal Leukemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing